Director-led regulatory support for pharmaceutical and biotechnology organisations planning or conducting clinical trials in Australia — from CTN or CTA pathway strategy and TGA requirements through HREC coordination, study start-up and Australian sponsor interfaces.
Clinical trials in Australia that use unapproved therapeutic goods are generally conducted under the Therapeutic Goods Administration’s Clinical Trial Notification (CTN) scheme or Clinical Trial Approval (CTA) scheme. The appropriate route depends on the therapeutic good, the available evidence, the nature of the trial and the capacity of the approving Human Research Ethics Committee (HREC) to assess the proposal.
For international sponsors, the regulatory pathway is only one part of start-up. The Australian trial sponsor, HREC review, institutional governance, trial documentation, TGA interactions and — for some gene therapy or GMO programmes — Office of the Gene Technology Regulator (OGTR) requirements need to be planned as connected workstreams.
Tricode Clinical provides a senior Australian regulatory interface across those workstreams, helping global and regional teams determine what is required, assign responsibilities clearly and progress the Australian component of the programme without creating an unnecessary full-service CRO layer.
CTN and CTA are different regulatory mechanisms. Tricode helps sponsors assess the pathway against the product and trial circumstances, prepare the required regulatory package and coordinate the TGA and HREC interfaces.
Under the CTN scheme, the TGA does not evaluate clinical trial data at the time of notification. The sponsor must first determine that the trial is eligible for CTN and, where both CTN and CTA may be available, the appropriateness of CTN should be considered with the approving HREC.
The CTA scheme involves TGA evaluation of scientific information about the unapproved therapeutic good before approval to supply it for the trial. The CTA pathway is mandatory in some circumstances, including certain Class 4 biologicals, and may be appropriate where additional TGA evaluation is required.
Good start-up depends on more than completing a notification or application form. The regulatory package must be internally consistent and aligned with the product, protocol, investigator information and Australian operating model.
Tricode can support regulatory assessment and preparation before submission, including confirmation of the proposed pathway, review of Australian-specific requirements, regulatory document preparation or review, and management of questions arising through the TGA or ethics process.
Australian clinical trial start-up involves ethical review as well as TGA requirements. HREC review, site or institutional governance and sponsor regulatory activities may proceed in parallel in some programmes, but responsibilities and dependencies need to be mapped carefully.
Tricode supports the regulatory and ethics interface rather than replacing the HREC, site governance team or CRO start-up function. We can coordinate document packages, respond to regulatory and ethics questions, track dependencies and work with the sponsor’s chosen CRO and sites so that Australian requirements are addressed consistently.
The National Statement on Ethical Conduct in Human Research 2025 took effect on 23 June 2026. Study teams should ensure ethics documentation and processes are aligned with the current National Statement and any applicable institutional or jurisdictional requirements.
Every clinical trial conducted in Australia must have a trial sponsor that is an Australian entity. An overseas company cannot itself be the Australian trial sponsor. That makes the local operating model an early regulatory decision for international pharmaceutical and biotechnology organisations.
Tricode can help an overseas sponsor define the Australian regulatory model, clarify interfaces with the global sponsor and CRO, and establish who is responsible for TGA submissions, HREC coordination, safety/regulatory communications and other local activities.
Where the engagement requires it and responsibilities are agreed, Tricode can also support the Local Sponsor interface. The exact legal and operational responsibilities are defined for each engagement rather than assumed from a generic service label.
For a broader Australian entry perspective, see Tricode Clinical’s Strategic Guide to Australian Market Entry.
Some gene therapy, viral-vector and other genetically modified therapeutic programmes require a separate assessment under Australia’s gene technology framework in addition to TGA, HREC and site requirements.
Human clinical trials involving a GMO may require a DNIR or DIR licence, depending on the proposed dealings. OGTR applications can also require Institutional Biosafety Committee (IBC) review. Classification should therefore be assessed early enough to coordinate the OGTR workstream with ethics and clinical trial start-up rather than treating it as a late add-on.
Tricode can support pathway assessment, application planning, IBC/OGTR coordination and alignment with the TGA and HREC workstreams where this is relevant to the programme.
Engagements are scoped around the sponsor’s actual gap. Tricode can provide a focused regulatory workstream or a broader Australian start-up interface without displacing established CRO, site or internal sponsor responsibilities.
Review product, protocol, sponsor structure, target sites and existing CRO/start-up responsibilities.
Assess CTN/CTA, Australian sponsor requirements and OGTR implications where relevant.
Prepare or review required documents and coordinate HREC, TGA and local interfaces.
Support questions, amendments, additional sites and ongoing Australian regulatory requirements.
Clients work directly with Tricode Clinical’s Director throughout the engagement. Read about Tricode Clinical’s Director-led regulatory experience.
Regulatory information on this page was reviewed on 4 August 2026 against current TGA, NHMRC and OGTR sources. Requirements should be confirmed for the specific product and trial before implementation.
Tell Tricode Clinical where your programme stands — whether you are assessing Australia, choosing between CTN and CTA, preparing ethics/start-up activities, establishing an Australian sponsor model or coordinating a gene therapy/GMO trial.
Discuss Australian study start-up